血管內(nèi)皮生長因子受體2(VEGFR2)重組蛋白
Recombinant Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1
- 編號(hào)RPB367Mu01
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU per 1μg (determined by the LAL method).
- 亞細(xì)胞定位細(xì)胞膜, 細(xì)胞質(zhì)
- 預(yù)測(cè)分子量32.4kDa
- 實(shí)際分子量34kDa(差異分析請(qǐng)參閱說明書)
- 片段與標(biāo)簽Asn46~Thr322 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)7.6
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請(qǐng)參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 864 ¥ 2160 ¥ 4320 ¥ 12960 ¥ 32400
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
Reconstitute in ddH2O to a concentration less than or equal to 0.1mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月，-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB367Mu02 | 血管內(nèi)皮生長因子受體2(VEGFR2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPB367Mu01 | 血管內(nèi)皮生長因子受體2(VEGFR2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB367Mu01 | 血管內(nèi)皮生長因子受體2(VEGFR2)多克隆抗體 | WB; IHC; ICC; IP. |
| PAB367Mu02 | 血管內(nèi)皮生長因子受體2(VEGFR2)多克隆抗體 | WB; IHC; ICC; IP. |
| LAB367Mu71 | 血管內(nèi)皮生長因子受體2(VEGFR2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEB367Mu | 血管內(nèi)皮生長因子受體2(VEGFR2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB367Mu | 血管內(nèi)皮生長因子受體2(VEGFR2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| APMIS | Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway [PubMed: 23398358] |
| Acta Biomater | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study [PubMed: 26689470] |
| Acta Biomaterialia | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study [Pubmed:26689470] |
| Journal?of?Cellular?Physiology | A?Human?3D?In?Vitro?Model?to?Assess?the?Relationship?Between?Osteoporosis?and?Disseminationto?Bone?of?Breast?Cancer?Tumor?Cells. [pubmed:27925188] |
| Regenerative Biomaterials | The directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic [10.1093/rb/rbx028] |
| International Journal of Immunopathology and Pharmacology | VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these?… [Pubmed:29985074] |
| JOURNAL OF DERMATOLOGICAL TREATMENT | Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris [Pubmed: 32043381] |
| Journal of Genetic Engineering and Biotechnology | Encapsulated VEGF 121-PLA microparticles promote angiogenesis in human endometrium stromal cells [33523322] |
| Mol Cell Biochem | Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy [34324118] |
| BMC Nephrol | Effect of subacute poisoning with lambdacyhalothrin on vascular endothelial growth factor 2 receptor in mice kidneys [Pubmed:35643467] |
留言咨詢
